Simeonov, Dimitre R.
Gowen, Benjamin G.
Boontanrart, Mandy
Roth, Theodore L.
Gagnon, John D.
Mumbach, Maxwell R.
Satpathy, Ansuman T.
Lee, Youjin
Bray, Nicolas L.
Chan, Alice Y.
Lituiev, Dmytro S.
Nguyen, Michelle L.
Gate, Rachel E.
Subramaniam, Meena
Li, Zhongmei
Woo, Jonathan M.
Mitros, Therese
Ray, Graham J.
Curie, Gemma L.
Naddaf, Nicki
Chu, Julia S.
Ma, Hong
Boyer, Eric
Van Gool, Frederic
Huang, Hailiang
Liu, Ruize
Tobin, Victoria R.
Schumann, Kathrin
Daly, Mark J.
Farh, Kyle K.
Ansel, K. Mark
Ye, Chun J.
Greenleaf, William J.
Anderson, Mark S.
Bluestone, Jeffrey A.
Chang, Howard Y.
Corn, Jacob E.
Marson, Alexander
Article History
Received: 30 September 2016
Accepted: 25 July 2017
First Online: 30 August 2017
Change Date: 13 June 2018
Change Type: Correction
Change Details: In this Letter, the data used to generate Extended Data Fig. 9d contained errors and were not correctly analysed. The corrected and reanalysed Extended Data Fig. 9d is shown in the Supplementary Information to the accompanying Amendment. The original Letter has not been corrected.
Competing interests
: H.Y.C. and W.J.G. are co-founders of Epinomics. A.M. and J.E.C. are co-founders of Spotlight Therapeutics. J.E.C. serves as an advisor to Mission Therapeutics and the Corn laboratory has received sponsored research support from AstraZeneca and Pfizer. A.M. serves as an advisor to Juno Therapeutics and PACT Therapeutics and the Marson laboratory has received sponsored research support from Juno Therapeutics and Epinomics.